Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
EDEdesa Biotech, Inc. logo

Edesa Biotech, Inc. (EDSA)

NASDAQ Capital Market · Currency in USD
$2.77 ▲ +0.01 (+0.36%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.86 ▲ +0.09 (+3.25%)
After hours: Oct 23, 7:29 PM ET

Summary

Previous Close
$2.76
Open
$2.70
Day's Range
$2.67 – $2.77
52 Week Range
$0.72 – $20.32
Volume
18,557
Avg. Volume
68,625
Market Cap
$26.68M
Beta (5Y Monthly)
1.06
PE Ratio (TTM)
--
EPS (TTM)
-$1.57
Earnings Date
Dec 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Edesa Biotech, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
17
CEO
Pardeep Nijhawan

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10.

Earnings

Next report: Fri, Dec 11, 2026
EPS estimate -$0.58
DateEst.Actual
Aug 13, 2026-$0.44-$0.60Miss
May 14, 2026-$0.24-$0.49Miss
Feb 13, 2026-$0.28-$0.28Beat
Dec 12, 2025-$0.27-$0.32Miss
Aug 8, 2025-$0.26-$0.25Beat
May 14, 2025-$0.30-$0.30Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on EDSA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.